Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

    European Heart Journal Date published:

  • Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

    Diabetes, Obesity and Metabolism Date published:

  • Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

    Diabetologia Date published:

  • Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

    Nephrology Dialysis Transplantation Date published:

  • Chronic kidney disease

    The Lancet Date published:

  • Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey

    BMJ Open Date published:

  • Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

    Stroke Date published:

  • Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

    Circulation Date published:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    The Lancet Date published:

  • Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

    Kidney International Date published:

  • Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

    Cardiovascular Research Date published:

  • Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

    Kidney International Reports Date published:

  • Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

    The Lancet Oncology Date published:

  • Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

    American Heart Journal Date published:

  • Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial

    Nephrology Dialysis Transplantation Date published: